Introduction {#S1}
============

Vaccinia virus (VACV) is the immunologically cross-protective orthopox virus found in the smallpox vaccine used in the eradication of smallpox.^[@R1]^ Although smallpox has been eradicated, there continues to be significant public health interest in smallpox and other orthopox viruses for multiple reasons: biodefense against weaponized poxviruses; continuing outbreaks of zoonotic orthopox virus infections; the use of vaccinia virus as a vector for cancer immunotherapy; and vaccines against other infectious agents.^[@R2]--[@R9]^ Thus, there continues to be a need for an increased understanding of poxvirus biology, host response to infection, and the immunologic mechanisms behind immunity to poxviruses.

Next generation sequencing (NGS) is a powerful technology that holds tremendous promise in the areas of systems biology^[@R10]^ and vaccinomics^[@R11]--[@R15]^ for developing a deeper understanding of the host response to both vaccines and viral infections. Here we describe the use of NGS mRNA-Seq to analyze transcriptomic changes occurring in PBMCs from smallpox vaccine recipients after vaccinia virus stimulation, with a focus on early, innate responses to viral stimulation.

Materials and Methods {#S2}
=====================

Subject Recruitment {#S3}
-------------------

Details regarding the cohort from which we selected subjects for use in this study have been previously published.^[@R16]--[@R19]^ Briefly, we selected 44 subjects from a cohort of 1,076 recipients of Dryvax®. All subjects had been vaccinated 1--48 months prior to enrollment, were generally healthy, had received no more than one dose of the smallpox vaccine, and were successfully immunized as evidenced by the characteristic vaccine "take." Subjects were enrolled at the Mayo Clinic (Rochester, MN) and from the Naval Health Research Center (NHRC, San Diego, CA). IRB approval from both centers (Mayo and NHRC) was obtained prior to subject enrollment, and informed consent was obtained in writing from all subjects. We selected subjects from among those individuals with the highest (n=21) and those with the lowest (n=23) vaccinia-specific neutralizing antibody titers.

Viruses and cell lines {#S4}
----------------------

The NYCBOH strain of vaccinia virus was purchased from ATCC (Manassas, VA), while the vSC56 strain of vaccinia virus was graciously provided by B. Moss (NIAID, Bethesda, MD). All virus strains were grown and titered according to established protocols. Hela, Hela S3, and Vero cells were also obtained from ATCC.

VACV neutralization assay {#S5}
-------------------------

VACV-specific, neutralizing antibody titers from each subject\'s serum sample were obtained using a high throughput neutralization assay developed at the FDA and further optimized in our lab as previously described.^[@R16],\ [@R20]^

Cell cultures, RNA extraction, mRNA-Seq {#S6}
---------------------------------------

PBMCs were stimulated for eight hours with or without live VACV NYCBOH at an MOI (multiplicity of infection) of 5. Following the incubation, RNAprotect reagent (Qiagen, Valencia, CA) was added to each culture and total RNA was extracted by RNeasy Plus mini Kit (Qiagen). The quantity and quality of each RNA sample were determined by Nanodrop (Thermo Fisher Scientific, Wilmington, DE) and by an Agilent 2010 Bioanalyzer (Agilent, Palo Alto, CA). cDNA libraries were created using the mRNA-Seq 8 Sample Prep Kit (Illumina, San Diego, CA) according to the manufacturer\'s directions. Sample preparation was performed in the Advanced Genomics Technology Center, Gene Sequencing core facility at the Mayo Clinic. Poly-A RNA was isolated using two rounds of magnetic purification with olido-dT coated beads. The purified poly-A RNA was fragmented and reverse transcribed into double-stranded cDNA fragments, which were attached to Illumina adaptor sequences. Library validation and quantification was carried out using DNA 1000 Nano Chip kits on an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA). cDNA libraries were loaded onto individual channels of each flow cell at a concentration of 5--7pM. Single end read sequencing was performed using the Genome Analyzer GAIIx (Illumina, San Diego, CA) with Illumina\'s Single Read Cluster Generation kit (v2) and 50 Cycle Illumina Sequncing Kit (v3). Flow cells were then analyzed with SCS v2.01 and v2.4. Image processing utilized the Illumina Pipeline Software v1.5 and FireCrest, bustard, ELAND, and CASAVA.^[@R21]^ Viral gene expression was determined by mapping sequencing reads to the vaccinia virus ACAM2000 (GenBank: AY313847.1) reference genome using Bowtie.

Statistical modeling and analyses {#S7}
---------------------------------

Randomized block principles were utilized to allocate specimens to flow cell and lane. Specifically, samples were randomly allocated to library preparation batch, flow cell, and lane, with the constraints that: 1) high and low responders were evenly balanced across flow cell and lane assignment; and 2) all samples for a given subject were assayed on the same flow cell.

Per-gene tests of statistical significance used generalized linear models^[@R22]^ assuming a Negative Binomial distribution.^[@R21]^ An offset of the 75th percentile^[@R23]^ was included as a normalization factor. Predictor variables were response status, stimulation status and the interaction of these two variables. The dispersion was allowed to vary across genes and was estimated via edgeR in an empirical Bayes-like manner sharing variance information across genes (moderated dispersion) with the prior.n parameter set to 3.^[@R24],\ [@R25]^ Due to the natural correlation between unstimulated and stimulated specimens within a subject, generalized estimating equations^[@R26]^ with an exchangeable correlation structure were utilized to properly estimate the variance. Genes with counts of at least 10 per response × stimulation combination or total counts of least 440 (i.e., an average of 5 counts/single lane) were analyzed; those with fewer counts were filtered out after calculating the normalization factor. False discovery rates (FDR) were computed as using standard methods.^[@R27],\ [@R28]^ Self-contained gene set tests^[@R29]^ were conducted using the Fisher\'s method^[@R30],\ [@R31]^ with restandardization.^[@R32]^ Gene sets were defined using immunologically based transcriptional modules.^[@R33]^ Both R^[@R34]^ and SAS^[@R35]^ computing packages were utilized.

Results {#S8}
=======

The high antibody group (n=21) had a median ID~50~ titer of 433.4 (IQR: 400.7 -- 481.9), while the low antibody titer group (n=23) had a median ID~50~ titer of 35.5 (IQR: 29.5 -- 40.2). Of note, 19 of the low group had antibody titers below the presumed protective threshold titer of 1:32.^[@R36]^ Each of these 44 subjects had two samples (uninfected, vaccinia-infected). We detected a similar number of reads between samples from high and low antibody (Ab) responders. The read counts between the stimulated and unstimulated samples were also comparable. We detected a mean of 11.3 million reads in the high titer, stimulated samples (10.9 million reads mapped to the human genome and 350,000 reads mapped to the vaccinia genome). In the high titer, unstimulated samples we detected a mean of 11.7 million reads (of which a mean of only 530 reads mapped to the viral genome).

Viral Stimulation and Host Gene Expression {#S9}
------------------------------------------

Viral stimulation had a dramatic effect on host gene expression, with over 1,200 genes exhibiting significant upregulation or downregulation between unstimulated and stimulated samples from all subjects (p \< 0.001 and false discovery rate \[FDR\] \< 0.01). A small subset of these genes with p-values less than 0.001, an FDR less than 0.01, and fold changes in expression \> 1.5 or \< 0.75 are listed in [Table 1](#T1){ref-type="table"} (The Supplemental Table contains the list of 1,000 genes, all with p\<0.001, that were used in the pathway analysis). These genes encode for: a number of histone proteins, cytokines and growth factors (IL3, IL18, IFNG, BMP3); chemokines and receptors (CXCL6, XCR1); G protein-coupled receptors (GPBAR1, GPR84, ADORA3); genes involved in lipid metabolism (APO2, OLR1); heat shock proteins (HSPA4L, HSPA6); cellular receptors with immune function (CD14, PDCD1LG2, TNFRSF10D); as well as a number of proteins specifically expressed in antigen presenting cells (C5orf20, MPEG-1, TREML4).

Interaction (High Responders vs Low Responders) Assessment of Gene Expression {#S10}
-----------------------------------------------------------------------------

Our study subjects were individuals from a large cohort who had the highest and lowest neutralizing antibody titers following smallpox vaccination, allowing us to compare high responder gene expression patterns following viral stimulation to the expression patterns in low responders. Given the large number of genes analyzed, we set a p-value cutoff of 5 × 10^−5^ and an FDR cutoff of 0.05. After applying these thresholds, three genes remained: KIR2DL3 (a killer cell immunoglobulin-like receptor); TPSD1 (a serine protease expressed in mast cells); and UNC13A (a phorbol ester receptor).

Pathway Analysis {#S11}
----------------

Recognizing that both infection and immune responses are the result of a highly complex, ordered series of events, and that contributions of individual genes may be quite small, we conducted both Metacore- and Ingenuity-based pathway analyses of host gene expression, using the top 1,000 genes with lowest p-values (all genes were p\<0.05. See [Supplemental Table 1](#SD1){ref-type="supplementary-material"}). Our analyses indicated that 15 Metacore pathways and five Ingenuity pathways were significantly enriched for differentially expressed genes upon viral stimulation ([Table 3](#T3){ref-type="table"}). These pathways involved innate pattern recognition receptors, FcR mediated phagocytosis, DC maturation, and oxidative stress responses. When comparing the high and low responders, we included the 593 genes with p\< 0.05. The Ingenuity enrichment analysis indicated that five pathways ([Table 4](#T4){ref-type="table"}) were differentially activated by these two immune response groups.

Geneset Analysis {#S12}
----------------

Gene set analysis was also conducted using the transcriptional gene modules described by Banchereau *et al*.^[@R37]^ Almost two-thirds of the transcriptional modules examined (164/260) exhibited significantly different (p \< 0.05) expression patterns upon viral infection. In contrast, only a single transcriptional module, M7.35 ([Table 6](#T6){ref-type="table"}), varied between high and low antibody responders. Gene set analysis using a subset of the BROAD genesets (those that included the keyword "immune" in their title/functional description) indicated that 200 of the 234 immunology-related genesets were differentially activated upon infection (p\<0.05), while geneset 132 (Innate_Immune_Response) was the only geneset with significant differences when comparing high and low antibody responders.

Viral Gene Expression {#S13}
---------------------

mRNA-Seq analysis provides both host and viral gene expression data, and allowed us to investigate host-pathogen interaction at the gene expression level. [Figure 1](#F1){ref-type="fig"} illustrates the average read count across all samples (infected read count -- uninfected read counts) for each of the \~250 open reading frames (ORFs) of vaccinia virus. Reads were mapped to the ACAM2000 sequence (Genbank: AY313848.1). We detected gene expression of each of the putative viral genes across a wide range of expression levels. Mean viral read counts ranged from 71 for the A38L semaphorin gene to 10,740 for the H5R transcription factor. Closer examination of the data found that genes with the lowest expression values were predominantly expressed late in the viral life cycle, while genes classified as "early" were expressed at significantly higher levels ([Figure 2](#F2){ref-type="fig"}). Vaccinia virus possesses a number of immunomodulatory proteins, almost all of which were detected in our samples. [Table 5](#T5){ref-type="table"} illustrates the expression levels of these viral genes. Interestingly, there were no significant differences between viral gene expression in samples from high and low antibody responders.

Discussion {#S14}
==========

The transcriptional profiles of PBMCs from individuals vaccinated with the Dryvax® smallpox vaccine were assessed after stimulation with vaccinia virus for eight hours. Our primary interest was to examine the early transcriptomic events that occur during innate responses to vaccinia virus in a mixed cell population. Because the subjects tested were taken from those with the two extremes of the humoral immune response after smallpox vaccination we also compared gene expression patterns in individuals with high and low vaccinia-specific neutralizing antibody responses. Transcriptomic analysis of the effect of vaccinia infection on host cells has previously been reported primarily in immortalized cell lines or single cell subsets, and has typically utilized microarray technology. Here we report the use of mixed-cell population PBMCs and NGS technology to assess global gene expression changes (both cellular and viral).

Individual Genes -- Stim/Unstim {#S15}
-------------------------------

Previous reports of host gene expression after vaccinia infection indicate a generalized downregulation of gene expression with a few select genes being upregulated. Rubins *et al* used microarrays to compare the effect of vaccinia and monkeypox infection on gene expression patterns in macrophages, fibroblasts, and HeLa cells and identified clusters of genes involved in innate immunity that were downregulated upon infection with VACV.^[@R38]^ Of the genes that they identified, in our experimental system only CXCL3 and STAT1 were downregulated, while the remaining genes exhibited insignificant changes in expression pattern. This is likely due to the different cell types examined. Rubins *et al* reported that their three cell types responded to viral infection with distinct differences in the gene expression pattern. Moss *et al*. used RNA sequencing to simultaneously analyze host and viral gene expression patterns after infection of HeLa cells with VACV.^[@R39]^ Four hours postinfection, they reported that 50--75% of host genes were decreased, while relatively few genes were overexpressed. They also indicated that expression of genes involved in NF-kB signaling, apoptosis, signal transduction, and other ligand-mediated signaling pathways was significantly altered. These results match our findings in a mixed-cell population ([Table 1](#T1){ref-type="table"}), indicating that general features of vaccinia infection may be shared across cell type. Interestingly, a number of histone genes exhibited strong (2--40 fold) upregulation upon vaccinia infection. This is similar to the results obtained in published reports using monkeypox and rabbitpox.^[@R40],\ [@R41]^ The authors speculate that cellular histone proteins may play a role in the organization and compaction of the viral genome.^[@R40]^ Our data support these earlier results; vaccinia virus elicits a similar effect as the other poxviruses. At this point it is too early to determine if this effect is the result of an antiviral host response or necessary for the poxvirus life cycle.

Several groups have shown that monocytes are particularly susceptible to vaccinia infection.^[@R42],\ [@R43]^ In our hands, flow cytometry analysis of PBMCs infected with vaccinia virus for eight hours indicate that the vast majority (\>85%) of monocytes are infected (data not shown) and our mRNA-Seq results indicated that a large number of monocyte/macrophage related genes (CD14, MPEG1, PDCD1LG2) have significantly altered expression. The CD14 gene produces a surface antigen expressed on macrophages (and to a lesser extent by some granulocytes and dendritic cells)^[@R44]^ that recognizes lipopolysaccharide,^[@R45]^ leading to activation of NF-kB, cytokine secretion, and initiation of inflammatory responses. MPEG1 encodes for a macrophage-specific protein with limited homology to perforin.^[@R46]^ PDCD1LG2 encodes for the programmed cell death 1 ligand 2 protein (a costimulatory molecule essential for T cell proliferation and IFNγ production) was downregulated by vaccinia infection. Importantly, IL18 gene expression was also downregulated upon infection. This cytokine has been shown to play a critical role in cellular responses to poxvirus infection,^[@R47]^ and we have previously reported that single nucleotide polymorphisms in both IL18 and IL18R genes are associated with variations in immune response following smallpox vaccination.^[@R19]^

Individual Genes -- Interaction {#S16}
-------------------------------

In the interaction analysis (differential effect of vaccinia stimulation in high and low responders), the KIR2DL3 gene was expressed at a significantly lower level in high responders and was downregulated upon vaccinia stimulation; in contrast, the low responders had higher baseline levels that increased upon viral stimulation. KIR2DL3 is a killer cell Ig-like receptor with two immunoglobulin domains and a longer cytoplasmic tail containing the immune tyrosine-based inhibitory motif (ITIM) that inhibits natural killer (NK) cell lysis of target cells expressing HLA-C alleles. KIR2DL3 has been linked to the resolution of hepatitis C virus infection, and this effect requires expression of both the NK receptor and its HLA-C1 ligand. It is possible that downregulation of this NK receptor in high responders allows for increased killing of vaccinia-infected cells; however, a cause and effect relationship, if one exists, between high responder status and KIR2DL3 expression is unclear and will require additional study. The second gene of interest, TPSD1, encodes for a mast cell serine protease. TPSD1 was expressed at similar levels in both high and low responders, but vaccinia stimulation resulted in increased expression in high responders and the opposite effect in low responders. TPSD1 contains a premature stop codon that leads to the loss of the C terminal regions necessary for optimal catalytic activity, but has been implicated in autoimmune pathology.^[@R48],\ [@R49]^ Although TPSD1 is largely inactive, an increase in gene expression may serve as an indicator of mast cell activity. Elevated levels may be due to mast cell recognition of vaccinia through IgE, or may merely be an indirect effect of other immune recognition pathways. The third significant gene, UNC13A, is a phorbol ester receptor similar to protein kinase C that is integral to synaptic vesicle priming.^[@R50]^ UNC13A expression levels were lower to begin with in high responders and decreased 20% upon viral stimulation, while in low responders background levels were high to begin with and exhibited a dramatic decrease (\~45%) upon stimulation (p = 2.96 × 10^−5^). UNC13A has also been shown to interact with Rab37 and control TNFα secretion in activated macrophages;^[@R51]^ however, TNFA mRNA expression did not differ between the high and low responder groups. The high Ab responders secreted greater amounts of TNFα (224.7 pg/ml versus 150.8 pg/ml in low responders), although the difference did not reach statistical significance (p=0.14).

Pathway Analysis {#S17}
----------------

Our pathway analyses indicated several important immune recognition pathways exhibiting differential activation upon viral stimulation, including complement, pattern recognition receptor, dendritic cell maturation pathways, as well as oxidative stress response, TREM1 signaling and FcγR-mediated phagocytosis. In spite of high level transcription of immunomodulatory genes, some innate immune recognition pathways are still activated in response to vaccinia infection, while others are suppressed. These results further illustrate the dynamic tension that exists between host and pathogen. TREM1 encodes for an Ig superfamily receptor expressed on monocytes and neutrophils and is upregulated in response to pathogen associated molecular patterns resulting in monocyte activation, secretion of IL-8, TNFa, MCP-1, and upregulation of adhesion and costimulatory molecules (ITGB1, CD40).^[@R52]^ Flow analysis of PBMCs from these subjects infected with vaccinia virus revealed a strong propensity for vaccinia virus to infect CD14+ monocytes (data not shown). Our transcriptomic data indicate that TREM1 and multiple downstream components of its signaling pathways are decreased upon viral infection, which might impair the immune function of infected monocytes and may lead to a decreased ability to prime adaptive immune responses.

Gene Set Analysis {#S18}
-----------------

Our gene set analysis comparing uninfected and infected samples indicated that a large number of transcriptional modules were differentially expressed. These modules were identified from subjects with a variety of immunologic conditions and so it is not surprising that many of the same modules would be affected by a viral infection. With the exception of module M7.35, we did not see significant differences between subjects with robust or weak antibody responses to smallpox vaccine. A potential functional role for this module has not yet been determined; however, several genes within the module are integral to innate and inflammatory responses (IL1R1, TLR2). Other genes include: the monocyte marker CD163; CLEC5A, a C-type lectin that serves as a macrophage recognition receptor for dengue virus stimulating pro-inflammatory responses;^[@R53]^ and the ORM1 and ORM2 proteins involved in transport of lipophilic compounds in the blood.^[@R54]^ The ORM proteins are also thought to regulate immune function during acute phase responses.^[@R55]^ Further examination of the contributions of these genetic elements in host responses to vaccinia infection is warranted and may provide additional insights into host-pathogen interactions. The Broad gene set M3064 (annotated by GO:0045087), containing 23 innate immune response genes, was the only geneset with significantly different expression when comparing high and low antibody responders. This gene set includes several defensins (DEFB1, DEFB118, DEFB127), IL12A and IL12B, as well as receptors involved in NK cell activity (CD1D, CRTAM, and NCR1). It is possible that high antibody responders have more innate responses that more readily recognize and react to vaccinia virus, and that this increased innate activity promotes stronger adaptive responses culminating in higher vaccinia-neutralizing antibody titer.

Viral Gene Expression Analysis {#S19}
------------------------------

Examination of the expression levels of viral genes indicated robust viral gene expression, predominantly in early genes ([Figure 2](#F2){ref-type="fig"}). We saw a striking similarity of viral gene expression between individuals with high and low immune response to the smallpox vaccine. One possible explanation may be the experimental setup in which subjects\' PBMCs were isolated, frozen, thawed, and placed in tissue culture with growth medium for an eight-hour *in vitro* infection. These conditions abrogate immediate binding by virus-specific serum antibody and may not allow sufficient time for the differential cellular immune reactivity between these two groups to alter the initial and early rounds of viral replication.

Assarsson *et al* used a genome-tiling array to measure expression kinetics of 223 vaccinia genes after infection of Hela cells and found that a majority of the viral genes were detected at the eight-hour time point.^[@R56]^ Several of the genes that they did not find expressed at any of their studied time points were expressed in our experiments (mean read counts are as follows: WR092 = 41 reads; WR097 = 766 reads; WR145 = 378 reads; WR162= 141 reads; WR206 = 5,022. See [Figure 1](#F1){ref-type="fig"}). Our data indicates that each of the 241 ACAM2000 ORFs were expressed in the stimulated samples and for some viral genes we identified relatively high expression levels (5,000--10,000 readcounts), indicating that strain and, more likely, cell-specific differences can dramatically affect viral gene expression and care must be taken when comparing expression data across studies.

A limitation of this study is the possible dilution of observable effects, given that each individual cell type may respond differently to vaccinia infection. On the other hand, this system more closely matches the *in vivo* environment during infection, and allows for the myriad cell-cell interactions that will occur during an infection or vaccination event. These interactions, involving either cell-to-cell contact, or mediated through soluble factors, are likely to alter the local microenvironment and the individual cell response to infection. The response of a mixed T cell:macrophage population may not reflect the response of a pure T cell population nor that a pure macrophage population, but, rather, will include at least four components: 1) a T cell response to infection; 2) a macrophage response to infection; 3) a T cell response to infected macrophages; and 4) a macrophage response to infected T cells. However, further studies on purified cell populations such as monocytes (given our findings with multiple monocyte-specific genes), or, alternatively, B cells or Th cells (given the neutralizing antibody titer-based subject selection) will yield valuable additional information. Our subjects were selected based on differences in humoral immunity and are likely to have different numbers of vaccinia-specific memory T and B cells. It is possible that inter-individual differences in the memory lymphocyte pool contribute to the differences seen in this study. We selected an eight hour time-point in order to allow for the development of early innate responses while minimizing the contribution of the memory T or B cells.

A strength of this study is the combined use of both individual analyses and pathway/geneset analyses along with highly sensitive NextGen Sequencing technology. Taken together, these separate analyses can identify individual components of the immune response, and the interaction of multiple signaling components. The geneset-type analyses have the additional benefit of reducing the number of associations to help offset false discovery.

Previous reports of gene expression in the context of vaccinia infection have focused on established cell lines or on primary cultures of single cell types. Our results indicate that numerous innate genes and pathways are activated upon vaccinia infection of a complex mixture of PBMCs. A number of chemokines, cytokines, interferons, and macrophage-associated genes exhibited significant downregulation upon infection. Upregulated genes included histones, IFNβ, IFNγ and heat shock proteins. Our data also indicate that notable differences in gene expression between high and low responders to the smallpox vaccine exist. It is possible that these differences are the result of divergent immunoregulatory processes in high and low responders. Further investigation of the effect of these loci on immune responses to viral vaccines may lead to important findings regarding genetic control of immune responses and the ability to use such information in engineering new vaccine candidates.^[@R10],\ [@R12],\ [@R15]^
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Effect of vaccinia stimulation on cellular gene expression.

  *[Cellular Genes Downregulated upon Vaccinia Stimulation]{.ul}*                                                                                                     
  ----------------------------------------------------------------- ---------------------------------------------------------------------------- ------ ------------- -------------
  CXCL6                                                             chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)         0.70   \< 1.00E-15   \< 1.00E-15
  ARNT2                                                             aryl-hydrocarbon receptor nuclear translocator 2                             0.71   \< 1.00E-15   \< 1.00E-15
  PDPN                                                              podoplanin                                                                   0.72   \< 1.00E-15   \< 1.00E-15
  CD14                                                              CD 14 molecule                                                               0.73   \< 1.00E-15   \< 1.00E-15
  S100A8                                                            SI00 calcium binding protein A8                                              0.73   \< 1.00E-15   \< 1.00E-15
  TREML4                                                            triggering receptor expressed on myeloid cells-like 4                        0.74   \< 1.00E-15   \< 1.00E-15
  S100A9                                                            S100 calcium binding protein A9                                              0.74   \< 1.00E-15   \< 1.00E-15
  PDCD1LG2                                                          programmed cell death 1 ligand 2                                             0.74   \< 1.00E-15   \< 1.00E-15
  THBS1                                                             thrombospondin 1                                                             0.74   \< 1.00E-15   \< 1.00E-15
  SIRPB2                                                            signal-regulatory protein beta 2                                             0.75   \< 1.00E-15   \< 1.00E-15
  MPEG1                                                             macrophage expressed 1                                                       0.75   \< 1.00E-15   \< 1.00E-15
  GPR84                                                             G protein-coupled receptor 84                                                0.72   \< 1.00E-15   8.86E-14
  C5orf20                                                           TRAF-interacting protein with forkhead-associated domain                     0.75   3.42E-14      2.66E-12
  IL18                                                              interleukin 18 (interferon-gamma-inducing factor)                            0.71   3.57E-14      2.77E-12
  OLR1                                                              oxidized low density lipoprotein (lectin-like) receptor 1                    0.72   1.42E-11      7.73E-10
  HNMT                                                              histamine N-methyltransferase                                                0.75   2.89E-11      1.48E-09
  HAMP                                                              hepcidin antimicrobial peptide                                               0.67   3.73E-11      1.88E-09
  C15orf38                                                          chromosome 15 open reading frame 38                                          0.75   7.43E-09      2.68E-07
  MYEOV                                                             myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)   0.72   1.76E-06      4.16E-05
  C20orf103                                                         chromosome 20 open reading frame 103                                         0.74   3.15E-06      6.96E-05
  SYT15                                                             synaptotagmin XV                                                             0.68   3.79E-06      8.22E-05
  TSP50                                                             Serine protease 50, involved in cellular proliferation                       0.55   7.23E-06      0.0001
  XCR1                                                              chemokine (C motif) receptor 1                                               0.75   1.50E-05      0.0003
  SEMA3A                                                            semaphorin 3A,secreted                                                       0.73   4.04E-05      0.0007
  SIRPD                                                             signal-regulatory protein delta                                              0.55   5.34E-05      0.0009
  APOC2                                                             apolipoprotein C-II                                                          0.73   6.50E-05      0.0011
  BMP3                                                              bone morphogenetic protein 3                                                 0.42   6.69E-05      0.0011
  ADORA3                                                            adenosine A3 receptor                                                        0.62   9.11E-05      0.0014
  KCNJ10                                                            potassium inwardly-rectifying channel, subfamily J, member 10                0.74   0.0001        0.0018
  NDP                                                               Norrie disease (pseudoglioma)                                                0.75   0.0002        0.0032
  C4BPB                                                             complement component 4 binding protein, beta                                 0.66   0.0002        0.0033
  GPBAR1                                                            G protein-coupled bile acid receptor 1                                       0.74   0.0003        0.0043
  PTGES                                                             prostaglandin E synthase                                                     0.69   0.000364055   0.004745659
  CHST6                                                             carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6                    0.52   0.000621449   0.007433113
  MFAP5                                                             microfibrillar associated protein 5                                          0.74   0.000878039   0.009960752

  *[Cellular Genes Unregulated upon Vaccinia Stimulation]{.ul}*                                                                                                             
  --------------------------------------------------------------- ----------------------------------------------------------------------------------- ------- ------------- -------------
  TNFRSF10D                                                       tumor necrosis factor receptor superfamily lOd, decoy with truncated death domain   1.90    \< 2.00E-16   \< 2.00E-14
  HIST4H4                                                         histone cluster 1, H41;                                                             2.31    \< 2.00E-16   \< 2.00E-14
  HIST1H4H                                                        histone cluster 1, H41;                                                             3.86    \< 2.00E-16   \< 2.00E-14
  HIST1H4C                                                        histone cluster 1, H41;                                                             5.68    \< 2.00E-16   \< 2.00E-14
  HSPA4L                                                          heat shock 70kDa protein 4-like                                                     5.74    \< 2.00E-16   \< 2.00E-14
  HIST1H4E                                                        histone cluster 1, H41;                                                             6.91    \< 2.00E-16   \< 2.00E-14
  HIST1H1D                                                        histone cluster 1, Hid                                                              9.37    \< 2.00E-16   \< 2.00E-14
  HIST1H1E                                                        histone cluster 1, Hie                                                              40.45   \< 2.00E-16   \< 2.00E-14
  IL3                                                             interleukin 3 (colony-stimulating factor, multiple)                                 3.35    2.22E-16      2.36E-14
  HIST1H2AM                                                       histone cluster 1, H2ag                                                             3.77    1.34E-09      5.40E-08
  IFNB1                                                           interferon, beta 1, fibroblast                                                      4.49    1.56E-08      5.29E-07
  EPHB3                                                           EPH receptor B3                                                                     1.65    3.39E-08      1.09E-06
  HIST1H2AE                                                       histone cluster 1, H2ae                                                             1.85    3.09E-07      8.55E-06
  HSPA6                                                           heat shock 70kDa protein 7 (HSP70B); heat shock 70kDa protein 6 (HSP70B\')          1.60    2.34E-06      5.34E-05
  HIST1H2BG                                                       histone cluster 1, H2bi;                                                            2.46    2.85E-06      6.34E-05
  RNF152                                                          ring finger protein 152                                                             1.82    4.33E-06      9.24E-05
  CH25H                                                           cholesterol 25-hydroxylase                                                          2.66    6.58E-06      0.000137
  HIST2H2AC                                                       histone cluster 2, H2ac                                                             1.90    3.11E-05      0.000545
  WFIKKN1                                                         WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 1       1.52    0.000187      0.002686
  LVRN                                                            laeverin, aminopeptidase Q                                                          2.12    0.000247      0.003421
  HIST1H2BN                                                       histone cluster 1, H2bn                                                             1.81    0.000419      0.005343
  IFNG                                                            interferon, gamma                                                                   2.57    0.00069       0.008117

p-value corrected for \_\_\_\_.

False discovery rate.

###### 

Differential effect of vaccinia stimulation on high and low responders

  Gene Name   Gene Description                                                  FC High responders   FC Low responders   p-value    FDR
  ----------- ----------------------------------------------------------------- -------------------- ------------------- ---------- ----------
  KIR2DL3     Killer cell immunoglobulin-like receptor, long cytoplasmic tail   0.88                 1.2                 1.55E-12   3.76E-09
  TPSD1       Tryptase, delta 1                                                 1.15                 0.81                1.68E-11   3.49E-08
  UNC13A      Unc-13 homolog A                                                  0.83                 0.62                2.96E-05   0.05

###### 

Pathways enriched in differentially expressed genes upon viral stimulation.

  Ingenuity Pathway                                                                                                            p-value
  ---------------------------------------------------------------------------------------------------------------------------- ----------------
  TREM1 Signaling                                                                                                              2.43 × 10^−11^
  Dendritic Cell Maturation                                                                                                    6.17 × 10^−9^
  NRF2-mediated Oxidative Stress Response                                                                                      3.48 × 10^−8^
  Role of PRR in Recognition of Bacteria and Viruses                                                                           3.67 × 10^−8^
  FcγR-mediated Phagocytosis in Macrophages and Monocytes                                                                      1.04 × 10^−7^
  **Metacore**                                                                                                                 **p-value**
  Immune response - Alternative complement pathway                                                                             1.03 × 10^−7^
  Immune response - Classical complement pathway                                                                               2.08 × 10^−7^
  Immune response - Lectin-induced complement pathway                                                                          1.79 × 10^−6^
  Immune response - FcγR-mediated phagocytosis in macrophages                                                                  7.82 × 10^−5^
  Apoptosis and survival - Inhibition of ROS-induced apoptosis by 17b-estradiol                                                2.01 × 10^−4^
  Cell adhesion - Chemokines and adhesion                                                                                      2.06 × 10^−4^
  Immune response - TREM1 signaling pathway                                                                                    2.98 × 10^−4^
  Inhibitory action of Lipoxins on Superoxide production in neutrophils                                                        4.83 × 10^−4^
  Immune response - Inhibitory action of lipoxins on superoxide production induced by IL-8 and Leukotriene B4 in neutrophils   4.83 × 10^−4^
  Cell adhesion - ECM remodeling                                                                                               5.37 × 10^−4^
  Development - EPO-induced MAPK pathway                                                                                       7.92 × 10^−4^
  Immune response - CCR3 signaling in eosinophils                                                                              9.21 × 10^−4^
  Chemotaxis - Lipoxin inhibitory action on fMLP-induced neutrophil chemotaxis                                                 1.07 × 10^−3^
  Immune response - HMGB1/RAGE signaling pathway                                                                               1.16 × 10^−3^

###### 

Pathways enriched in differentially expressed genes comparing high/low responders.

  Ingenuity Pathway                           p-value
  ------------------------------------------- ---------
  Nitrogen Metabolism                         0.002
  Mitochondrial Dysfunction                   0.002
  Dopamine Receptor Signaling                 0.003
  EIF2 Signaling                              0.004
  Corticotropin Releasing Hormone Signaling   0.008
  Biosynthesis of Steroids                    0.018
  Aldosterone Signaling in Epithelial Cells   0.020
  Lysine Biosynthesis                         0.021
  Endothelin-1 Signaling                      0.028
  Starch and Sucrose Metabolism               0.030
  Systemic Lupus Erythematosus Signaling      0.030
  T Helper Cell Differentiation               0.032
  Signaling by Rho Family GTPases             0.036
  LXR/RXR Activation                          0.037
  Sonic Hedgehog Signaling                    0.038
  Melatonin Signaling                         0.038
  Regulation of eIF4 and p70S6K Signaling     0.040

###### 

Immunomodulatory Gene Expression by Vaccinia Virus.

  ACAM Name   COP Name     Function                                Median (IQR) \# Reads Stim   Median \# Reads Unstim
  ----------- ------------ --------------------------------------- ---------------------------- ------------------------
  001         C23L, B29R   Chemokine binding protein               1,006 (485 -- 1,546)         1
  002         C22L, B28R   TNFaR                                   166 (103 -- 223)             0
  003                      TNFaR                                   231 (122 -- 305)             0
  013         C12L         Serpin 1,2,3                            3,640 (2,026 -- 5,187)       7
  014         C11R         EGF                                     1,254 (577 -- 1,973)         2
  015         C10L         IL-1R antagonist                        1,244 (672 -- 1,886)         2
  018                      apoptosis, host defense mod             92 (45 -- 145)               0
  019                      IL-18 binding prot                      2,147 (1,158 -- 3,661)       4
  031         C4L          IL 1R antagonist                        502 (241 -- 706)             1
  032         C4L          IL 1R antagonist                        666 (304 -- 882)             1
  033         C4L          IL 1R antagonist                        155 (66 -- 210)              0
  037         N1L          NFkB inh./virokine                      3,230 (1,684 -- 4,651)       4
  042         M2L          NF-kB Inh                               4,554 (3,176 -- 7,382)       8
  045         K3L          IFN resist, PKR inh                     335 (215 -- 785)             1
  049         K7R          Inh IFNb signal                         572 (238 -- 750)             1
  069         E3L          IFN resist, PKR inh, dsRNA binding      9,325 (5,180 -- 15,798)      16
  183         A46R         IL-1 signal inhibitor TLR-like          4,233 (2,232 -- 6,450)       8
  189         A52R         TLR/IL-1 signal inhibitor               486 (243 -- 666)             1
  201         B8R          IFNg Receptor                           10,664 (6,994 -- 14,488)     16
  206         B13R         SPI-2, crmA, IL-1 convertase,           4,110 (2,351 -- 5,452)       5
  207         B14R         SPI-2, crmA, IL-1 convertase            7,536 (4,242 -- 10,295)      9
  212         B19R         secreted IFNa/b receptor                7,452 (4,629 -- 10,948)      13
  224                      IL 18 binding                           1,235 (700 -- 2,270)         2
  229         C12L         SPI-1                                   4,506 (2,566 -- 6,306)       8
  239                      TNFaR like                              210 (140 -- 310)             0
  240                      TNFaR like                              187 (110 -- 223)             0
  034         C3L          Complement Binding                      72 (46 -- 134)               0
  044         K2L          serpin, SPI-3, host defense modulator   263 (167 -- 513)             0
  190         A53R         TNFR Crm C                              538 (279 -- 789)             1
  209         B16R         IL-1b Receptor                          73 (42 -- 125)               0

###### 

Transcriptional Module M7.35

  Symbol      Description
  ----------- -----------------------------------------------------------------------------------------------------------------------------------
  ANKRD22     Homo sapiens ankyrin repeat domain 22 (ANKRD22), mRNA.
  CCNA1       Homo sapiens cyclin A1 (CCNA1), mRNA.
  CD163       Homo sapiens CD163 molecule (CD163), transcript variant 1, mRNA.
  CD177       Homo sapiens CD177 molecule (CD177), mRNA.
  CLEC5A      Homo sapiens C-type lectin domain family 5, member A (CLEC5A), mRNA.
  CREB5       Homo sapiens cAMP responsive element binding protein 5 (CREB5), transcript variant 4, mRNA.
  DAAM2       Homo sapiens dishevelled associated activator of morphogenesis 2 (DAAM2), mRNA.
  ECHDC3      Homo sapiens enoyl Coenzyme A hydratase domain containing 3 (ECHDC3), mRNA.
  GPR84       Homo sapiens G protein-coupled receptor 84 (GPR84), mRNA.
  IL1R1       Homo sapiens interleukin 1 receptor, type I (IL1R1), mRNA.
  KIAA1026    Homo sapiens kazrin (KIAA1026), transcript variant B, mRNA.
  LOC400793   PREDICTED: Homo sapiens hypothetical LOC400793, transcript variant 2 (LOC400793), mRNA.
  LOC401233   Homo sapiens similar to HIV TAT specific factor 1; cofactor required for Tat activation of HIV-1 transcription (LOC401233), mRNA.
  LOC651612   PREDICTED: Homo sapiens hypothetical protein LOC651612 (LOC651612), mRNA.
  METTL7B     Homo sapiens methyltransferase like 7B (METTL7B), mRNA.
  MYO10       Homo sapiens myosin X (MYO10), mRNA.
  OLAH        Homo sapiens oleoyl-ACP hydrolase (OLAH), transcript variant 1, mRNA.
  ORM1        Homo sapiens orosomucoid 1 (ORM1), mRNA.
  ORM2        Homo sapiens orosomucoid 2 (ORM2), mRNA.
  PCOLCE2     Homo sapiens procollagen C-endopeptidase enhancer 2 (PCOLCE2), mRNA.
  PFKFB2      Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2), transcript variant 2, mRNA.
  SLC1A3      Homo sapiens solute carrier family 1 (glial high affinity glutamate transporter), member 3 (SLC1A3), mRNA.
  SLC2A11     Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 11 (SLC2A11), transcript variant 3, mRNA.
  SYN2        Homo sapiens synapsin II (SYN2), transcript variant IIa, mRNA.
  TDRD9       Homo sapiens tudor domain containing 9 (TDRD9), mRNA.
  TLR2        Homo sapiens toll-like receptor 2 (TLR2), mRNA.
  ZDHHC19     Homo sapiens zinc finger, DHHC-type containing 19 (ZDHHC19), mRNA.
